Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17055863 | 0.90 | L3MBTL1 (0.59) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL7470264 | 0.90 | L3MBTL1 (0.59) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL18581866 | 0.90 | USP2 (0.56) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL18619321 | 0.89 | USP2 (0.53) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL7476299 | 0.83 | USP2 (0.47) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL17055845 | 0.83 | USP2 (0.47) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL8046306 | 0.83 | BRD4 (0.53) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL18581515 | 0.82 | KMT2A (0.49) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL2238303 | 0.81 | SMYD3 (0.59) | USP2GAAMEN1KMT2AALOX5 | |
| SCHEMBL12362558 | 0.81 | SMYD3 (0.59) | USP2GAAMEN1KMT2AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417052-B2 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | SANKYO COMPANY, LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | RENASCIENCE CO., LTD (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1679310-A1 | PHENYLENE DERIVATIVE HAVING TETRAZOLE RING OR THIAZOLIDINEDIONE RING | Sankyo Company, Limited (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105846-A1 | Phenylene derivative having tetrazole ring or thiazolidinedione ring | JAK2, ABL1, CYP3A5 | USP2 4581/4885GAA 3291/4885MEN1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.